Sign In
Buy AMPE
$0.183
+0 (+0%)
At Close: Jun 03, 2026
7 Penny Stocks Worth the Danger as Pandemic Catalyzes Growth
06:43pm, Friday, 31'st Jul 2020
Investing in penny stocks is primarily the domain of highly risk-averse market participants. The risk profile of penny stocks is, of course, a double-edged sword: investors could lose a lot of money o
Ampio Starts Patient Enrollment in its Ampion COVID-19 Program
12:00pm, Thursday, 23'rd Jul 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent infl
Mid-Morning Market Update: Markets Down; AT&T Earnings Beat Estimates
12:00am, Thursday, 23'rd Jul 2020
Following the market opening Thursday, the Dow traded down 0.26% to 26,936.51 while the NASDAQ fell 0.11% to 10,692.02. The S&P also fell, dropping 0.04% to 3,274.73.
The U.S...
Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 related Syndrome
12:00pm, Monday, 20'th Jul 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today ann
Outlook of Diabetic Macular Edema (DME) 2020-2025 - Current Landscape and the Way Forward - ResearchAndMarkets.com
12:00am, Monday, 13'th Jul 2020
The
2020 Study into the Global Macular Edema Industry - Market Size and Drug Sales - ResearchAndMarkets.com
12:00am, Thursday, 02'nd Jul 2020
The
Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%
03:31pm, Monday, 29'th Jun 2020
Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
-$0.04 Earnings Per Share Expected for Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) This Quarter
12:04pm, Monday, 29'th Jun 2020
Wall Street brokerages expect Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) to post earnings of ($0.04) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Ampio
Regeneron's Latest Approval, And Other News: The Good, Bad And Ugly Of Biopharma
02:54pm, Monday, 22'nd Jun 2020
Regeneron's dupixent gets an approval. AbbVie walks out of Assembly Biosciences partnership. Ampio will begin a COVID-19 trial.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shares Gap Up to $0.57
02:49am, Sunday, 21'st Jun 2020
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) gapped up prior to trading on Friday . The stock had previously closed at $0.33, but opened at $0.57. Ampio Pharmaceuticals shares last traded at $0.57, w
Italy sewage study suggests COVID-19 was there in December 2019 Scientists in Italy have found traces of the new coronavirus in wastewater collected from Milan and Turin in December 2019 - suggesting
Ampio to study experimental drug in COVID-19 patients
12:43pm, Friday, 19'th Jun 2020
U.S. drug developer Ampio Pharmaceuticals Inc said on Friday it would begin an early stage study of its experimental treatment, Ampion, in COVID-19 patients after it received regulatory clearance from
Ampio to Start First Clinical Trial in COVID-19 Program
12:00pm, Friday, 19'th Jun 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company"), is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As par
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
09:18am, Wednesday, 10'th Jun 2020
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d
